CME Group
CME
$290.12
-4.05%
CME Group Inc. operates the world's leading and most diverse derivatives marketplace, providing a platform for trading futures and options contracts across interest rates, equity indexes, foreign exchange, energy, agricultural products, and metals. As a dominant global exchange operator, the company possesses a formidable competitive moat derived from its scale, deep liquidity pools, and ownership of benchmark products like Eurodollar and S&P 500 futures. The current investor narrative centers on the stock's performance as a play on sustained market volatility and elevated interest rates, with recent news highlighting robust dividend payouts and the company's direct benefit from heightened trading activity amid economic uncertainty, though this is tempered by concerns over a potentially delayed Federal Reserve easing cycle.…
CME
CME Group
$290.12
Related headlines
CME 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CME Group's 12-month outlook, with a consensus price target around $377.16 and implied upside of +30.0% versus the current price.
Average Target
$377.16
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$232 - $377
Analyst target range
CME is covered by 7 analysts, indicating solid institutional research interest. The consensus sentiment appears mixed, as evidenced by recent institutional actions including an upgrade to 'Buy' from TD Cowen and a downgrade to 'Hold' from Argus Research, alongside maintained 'Overweight', 'Equal Weight', and 'Underweight' ratings from other major firms. While a precise consensus recommendation and average target price are not provided in the data, the range of actions and the 7-analyst coverage point to a stock where views are divided, likely reflecting debates over the sustainability of trading volumes in different macroeconomic regimes. The wide dispersion in analyst views, from 'Underweight' (JP Morgan) to 'Overweight' (Morgan Stanley), signals high uncertainty regarding the near-term catalyst path and the stock's sensitivity to interest rate expectations; this lack of strong consensus can lead to higher volatility as the narrative shifts, though the company's fundamental strength and dividend provide a floor for valuation.
Bulls vs Bears: CME Investment Factors
The evidence tilts slightly bullish, anchored by CME's unparalleled financial fortress, exceptional profitability, and defensive market profile, which provide a high floor for valuation. However, the bear case presents a compelling near-term challenge centered on valuation and momentum. The single most important tension in the investment debate is whether CME's premium valuation (23.2x forward P/E) can be sustained in the face of a potential macroeconomic regime shift away from the high-volatility, high-rate environment that has recently benefited its volumes. The resolution of the Federal Reserve's policy path and its impact on trading activity will be the decisive factor for the stock's direction over the next 12 months.
Bullish
- Exceptional Profitability & Margins: CME's Q4 2025 net margin expanded to 62.0% from 57.3% a year ago, demonstrating powerful operating leverage. This is supported by a gross margin of 85.4%, highlighting the high-margin nature of its exchange and clearing franchise.
- Fortress Balance Sheet & Cash Flow: The company has a negligible debt-to-equity ratio of 0.13 and generated $4.19 billion in trailing free cash flow. This immense financial strength funds a substantial dividend (payout ratio of 97%) and provides a significant margin of safety.
- Defensive, Low-Beta Profile: With a beta of 0.26, CME is 74% less volatile than the broader market. This makes it a compelling defensive holding, particularly attractive during periods of market uncertainty, as evidenced by its recent outperformance year-to-date (up 10.8% vs. SPY's 8.4%).
- Revenue Growth & Diversification: Q4 2025 revenue grew 8.1% year-over-year to $1.65 billion, showing resilience. Revenue is diversified beyond core clearing fees, with MarketData and Other segments contributing $321 million, reducing dependence on pure trading volumes.
Bearish
- Valuation Premium & Slowing Momentum: Trading at a forward P/E of 23.2x and a PEG ratio of 1.58, the stock prices in growth but may be vulnerable to multiple compression. This is compounded by a significant loss of price momentum, with the stock down 1.4% over 3 months while the SPY gained 8.4%.
- Macro Sensitivity to Interest Rate Cycle: Recent news highlights a delayed Fed easing cycle, which threatens the 'volatility play' narrative. A prolonged period of high rates could eventually dampen derivatives trading activity, pressuring the primary revenue driver of clearing fees.
- Analyst Sentiment Lacks Conviction: Coverage by 7 analysts shows a wide dispersion of views, from 'Underweight' to 'Overweight', indicating high uncertainty on near-term catalysts. The lack of a strong consensus suggests the stock lacks a clear, near-term positive narrative to drive it higher.
- Technical Consolidation Near Highs: The stock is trading at 78% of its 52-week range ($257.17 to $329.16), having failed to break above the $329 resistance. The 3-month relative strength of -9.81 against the SPY signals pronounced underperformance and potential distribution.
CME Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 9.07% 1-year price change, but is currently consolidating after a significant rally. With a current price of $298.86, it is trading at approximately 78% of its 52-week range ($257.17 to $329.16), positioning it closer to the upper band and suggesting the momentum may be maturing, requiring a catalyst for a new breakout. Recent momentum shows a stark divergence from the longer-term trend, with the stock down 1.39% over the last three months and up a modest 0.66% over the past month, indicating a significant loss of upward thrust and potential consolidation or distribution after the earlier advance. This deceleration is further highlighted by a relative strength 3-month figure of -9.81 against the SPY, showing pronounced underperformance. Key technical support is anchored at the 52-week low of $257.17, while immediate overhead resistance sits at the 52-week high of $329.16; a decisive breakout above $329 would signal a resumption of the primary bull trend, while a breakdown below $257 would indicate a major trend reversal. The stock exhibits low systematic risk with a beta of 0.26, meaning it is 74% less volatile than the broader market, which is a critical consideration for risk-averse portfolios seeking defensive exposure to financial infrastructure.
Beta
0.26
0.26x market volatility
Max Drawdown
-13.8%
Largest decline past year
52-Week Range
$257-$329
Price range past year
Annual Return
+4.4%
Cumulative gain past year
| Period | CME Return | S&P 500 |
|---|---|---|
| 1m | +0.9% | +4.6% |
| 3m | -4.5% | +8.3% |
| 6m | +6.2% | +12.5% |
| 1y | +4.4% | +25.0% |
| ytd | +7.6% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CME Fundamental Analysis
CME exhibits a stable and growing revenue trajectory, with Q4 2025 revenue of $1.65 billion representing an 8.1% year-over-year increase, and sequential quarterly revenue over 2025 showing resilience between $1.54 billion and $1.69 billion. The growth is primarily driven by its core clearing and transaction fees, which contributed $1.33 billion in the latest period, supported by MarketData and Other Revenue segments adding $208 million and $113 million, respectively, indicating a diversified and high-quality revenue stream. Profitability is exceptionally strong, with Q4 2025 net income of $1.17 billion and a robust net margin of 62.0%, supported by a gross margin of 85.4%; margins have expanded from the year-ago quarter's net margin of 57.3% and gross margin of 85.5%, demonstrating impressive operating leverage and pricing power in its franchise. The company's balance sheet and cash flow are fortress-like, featuring a minimal debt-to-equity ratio of 0.13, an exceptionally high current ratio of 93.0, and annual free cash flow of $4.19 billion, which provides immense financial flexibility for dividends, share buybacks, and strategic investments without reliance on external financing.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$4.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CME Overvalued?
Given CME's substantial and consistent profitability, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 24.3x and a forward PE of 23.2x, with the minimal gap between the two suggesting the market anticipates stable, rather than accelerating, earnings growth in the near term. Compared to sector averages (data not available in the provided set for a direct industry PE), the stock's premium must be justified by its exceptional qualities; however, the provided PEG ratio of 1.58 suggests the market is pricing in growth, but not at an excessive rate relative to its earnings expansion. Historically, the stock's own trailing PE has fluctuated, with recent quarterly data showing a range from approximately 19.9x to 26.8x over the past two years; the current PE of 24.3x sits near the midpoint of this recent historical band, indicating the stock is neither egregiously expensive nor cheap based on its own trading history, but rather fairly valued relative to its recent earnings profile.
PE
24.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 19x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CME's financial risks are minimal, characterized by a fortress balance sheet with a debt-to-equity of 0.13 and a staggering current ratio of 93.0. The primary operational risk is revenue concentration in clearing and transaction fees ($1.33B of $1.65B in Q4), making top-line growth inherently tied to market volatility and volume, which can be cyclical. While margins are expanding (net margin from 57.3% to 62.0% YoY), any sustained decline in trading activity would pressure this high-margin revenue stream, though the company's low cost structure provides a buffer.
Market & Competitive Risks: The key market risk is valuation compression. Trading at a forward P/E of 23.2x and a PEG of 1.58, the stock carries a premium that is justified by quality but vulnerable if growth expectations moderate. The stock's low beta (0.26) offers defensive characteristics but also means it may lag in strong bull markets, as seen in its 1-year underperformance vs. the SPY by 16.1 percentage points. Competitive disruption is a low-probability but high-impact risk, though CME's ownership of benchmark contracts and deep liquidity pools constitute a formidable moat.
Worst-Case Scenario: The most damaging scenario would be a combination of a sharp, sustained decline in market volatility and a rapid Federal Reserve easing cycle that reduces interest rate uncertainty, severely depressing volumes across CME's core interest rate and equity index complexes. Concurrently, a broad market sell-off could trigger multiple compression for even quality names. In this adverse scenario, the stock could realistically re-test its 52-week low of $257.17, representing a downside of approximately -14% from the current price of $298.86. The historical max drawdown of -13.85% provides a similar guide for potential loss magnitude.